PCSA: Merger and funding enable rapid phase II development of VT-7208, a differentiated BTK inhibitor
A recent merger and $200M PIPE have positioned the company to advance VT-7208, a next-gen BTK inhibitor, into three phase II trials targeting food allergy, CSU, and relapsing MS. Early data show strong safety, CNS penetration, and durable target engagement, with a differentiated profile from compet…